

Iranian Childhood Cancer BioBank (ICCB)

Peyman Eshghi

Prof. of Pediatric Hematology & Oncology
Mofid Children's Hospital

SBMU

Mashad

19 & 20-06-1404

مرکز تحقیقات بیماری های خونی مادرزادی کودکان





Biobank: Definition

- An organized collection of human **biological material**
- **The associated data**, stored in a readily **analysable format**
- for a **population** or a large subset of a population



Different Types of Biobanks

- Human, microorganisms, animals, plants
- Biomedical research
- Medical archives
- Therapy
 - Blood banks
 - Bone marrow
 - Cord blood
 - Stem cells
 - Organs

مرکز تحقیقات بیماری‌های فونی مادرزادی کودکان

Clinical Samples: Opportunities

- Tissues, blood, saliva, urine, feces, cells, hair, nail
 - Discovery of **gene function**
 - Identification of **disease relevance** of genes
 - Identification of new **targets for drug** discovery
 - Identification and **validation of biomarkers** for individualized therapy
- Biobanks as biological resources along with patient-related data are required for **personalized medicine ,basic, clinical and translational research.**

مرکز تحقیقات بیماری‌های فون‌ی مادرزادی کودکان

Biobank Formats

➤ Population-based

- Random cohorts
- Twin-registries
- Population isolates
- Entire cohort

➤ Disease-oriented

- Disease-specific cohorts
- **Tissue banks**

مرکز تحقیقات بیماری‌های فونی مادرزادی کودکان

Childhood Cancer and Blood Research (CCBR) BioBank, BC Children's Hospital, Vancouver, BC

The aim of the CCBR BioBank is to provide researchers with high quality biospecimens from pediatric patients with blood disorders in an ethical manner.

The CCBR BioBank

The CCBR BioBank was established in September 2011 to collect and store biospecimens from pediatric patients with hematological disorders. The CCBR is governed by a research ethics board (REB) and a management committee and


Patients who donate to the BioBank under the research project will be used in a research project approved by a research ethics board (REB) and a management committee of the BioBank.

Mouse expansions

The CCBR BioBank has the ability to expand our acute lymphoblastic leukemia cells in immune deficient mice allowing us to generate >100 times the number of cells for purposes. This allows for highly sensitive detection of minimal residual disease, evaluation of novel therapies, and growth factor

is from the

in the CCBR BioBank committee whose role is to ensure the application.



Why are modern Biobanks needed?

Traditionally, human biological samples are collected by individual researchers in academic organizations. Limitations include:

- Too few number of patients
- Non-standardized :
 - sample collection and processing
 - Storage space quality and quantity
- Utilization of samples usual suboptimal: consent that limits the use of samples
- Heavy bureaucracy, limited project time
- Limitations in bioinformatics and biostatistics



When biobanking professionally?

- **Good quality human biological samples, linked to a up-to-date clinical database, are a prerequisite for contemporary translational studies using modern laboratory techniques :**
 - **Sample collecting protocols are plain and reproducible**
 - You know **where** your samples are and **how many** you have
 - You know how much there is sample **left**
 - **Identification** of the tube is clear
 - **Sample quality** is being checked **during storage**
 - Sample processing and storage **steps are recorded**
 - Sample related **data is recorded**



Why biobank **FRESH TISSUE**?

- **Fresh-frozen tissues** provide a long time molecular ‘snap shot in time’ of what is happening in a cancer or other pathological tissues to identify the underlying cause of the disease :
 - Histopathological data from Formalin Fixed Parafin Embded (FFPE)
 - DNA,
 - RNA and
 - **Proteins, Enzymes, etc.**
- **The material is very valuable as it is from real life human illnesses** and usually is in very short supply.
- A good specimen is qualified as having **over 75% cancer cells** , without effect on **patient diagnosis**

مرکز تحقیقات بیماری های خونی مادرزادی کودکان

A selection of fresh tissue preservation techniques

Parameters considered	Celluar morphology	Biomolecule preservation/ extraction	Ease of use	Cost
Snap freezing	Poor/temp cycling	Initially excellent, limited rounds of freeze/thaw Poor morphology	Pathologist, liquid N ₂ Local -80°C freezer	High
OCT embedded	Poor/temp cycling	Proteins not Available for mass spect	Same as above	High
Paxgene (Qiagen)	Literature says good	Literature says good, patiented extraction kit	Two vials of solution required	Very high
RNA later (Ambion)	Poor/not used For diagnostics	RNA good DNA extraction phen:chloro	Good RNA Poor DNA	High

Biospecimen Vacuum System

Your choice of
fixation protocols

Formalin fixation? ☒ **Yes**

Selected blocks are inserted in cassettes for fixation in formalin under controlled conditions (eg. FixSTATION)

Molecular studies? ☒ **Yes**

Specimen can be fixed in an ethanol based molecular fixative (eg. FineFIX).

Tissue banking? ☒ **Yes**

Selected blocks can be frozen for tissue banking.

Standardization and documentation of the pre-analytical step



FORMALIN-FREE

TissueSAFE

High vacuum biospecimens transfer system

Congenital Hematologic
Research Center

مرکز تحقیقات بیماری های خونی مادر

An integrated hospital biobanking needs to know/control/document all of these processes

Medical Treatment



Donor Consent

Medical/Surgical Procedures



Transport



Receiving



Processing




Storage



Annotation



Quality



Release, Distribution Transport

Scientific Analysis

Restocking/ Destruction

Medical Research

Measure in Minutes

Measure in Years

Pre-acquisition

- Antibiotics
- Other drugs
- Type of anesthesia
- Anesthesia duration
- Arterial clamp time
- Warm Ischemia
- Cold Ischemia

Acquisition

- Processing Time
- Temperature
- Warm Ischemia
- Cold Ischemia
- Fixation Agent
- SOP's / Workinstructions

Post Acquisition

- Storage Media
- Storage Method
- Storage Temperature
- Quality Controls
- Pathology Review
- Disease Site
- Clinical Data
- Data Standards
- SOP's / Workinstructions


Release

- Study Design
- Multidisciplinary
- Ethics
- Statistics
- Equipment
- Cohort Definition
- SOP's / Workinstructions
- Material Transfer Agreement


مرکز

Global market demand for biospecimens

Figure 1: Global Market Value of the Demand For Human Biospecimens and Related Services



Biobank Total Cost of Ownership




Iranian Childhood Cancer BioBank (ICCBB)

<https://iccbb.ir/En>

Iranian Childhood Cancer BioBank

زیست بانک سرطان کودکان ایران

Home About Collections Access Policy Links Multimedia Contact



8000 Sample

720 Participant

0 Project

Iranian Childhood Cancer BioBank

زیست بانک سرطان کودکان ایران

Home About Collections Access Policy Links Multimedia Contact

Access Policy

Statistics of samples in biobank

Forms and tables

Collection instructions

Home / Access Policy

Introduction

- Iranian Children's Cancer Biobank (ICCB) is **the first pediatric biobank center in Iran** aims to set up a **centralized biobank** to collect a variety of biological samples and associated clinical data in children with **newly diagnosed or relapsed in the age range of 0 to 18 years**
- Special challenges of pediatric cancer biobanks:
 - Low incidence in comparison with adult cancer
 - the need for a long-term collection of rare tumors,
 - high tumor diversity,
 - the difficulty of working with children, as well as the limited volume of samples (blood and tissue) in children

Requirements & Activities

(Sept.2016 to July 2022)


- **Proposal** accepted and the financial support provided by the National Institute of Medical Sciences and Research Development (**NIMAD**) in **2016**
- **Ethical issues** was approved by the National Ethical Committee of the Ministry of Health and Medical Education of Iran (**IRnNIMAD REC 1396 061**) in **2017**
- Well designed **Standard Operating Procedures (SOP)** for all aspects of the biobank procedures, including sample collection, processing, storage, and clinical data recording.
- Human power:
 - Enough , Expert and Cooperative
 - Coordination with surgeons, oncologists, and pathologists, nurses and all of the stalk holders of the centers in in three cities in Iran :Tehran,Mashad,Urmia

➤ **Setting up the ICCBB laboratory:**

- Standard space and location for site (ICCBB is located at Mofid Hospital in Tehran, Iran)
 - Safe, **24H/7days** supervised and controllable
 - Good and **easy access for handling** of all of the equipments
- Purchase and Instalation of equipment: two (-80°C) freezers, a refrigerator, four liquid nitrogen tanks, four small portable transfer LN tanks, a class II biosafety cabinet, a centrifuge machine, a barcode scanner and label printer, a freezer temperature alarm system ,Tissue-safe vaccume transfer system.
- Recruiting patients and collecting samples, began in January 2017
- **Collection of samples** :Buffy coat PBMCs , serum and plasma, Bone marrow and tissue samples, hair and Urine from patients ,and blood samples from parents.
- **Storage of samples :**
 - All plasma, serum, and urine samples were stored in -80°C ultra-freezers located in the biobank room,
 - PBMC samples were stored at -80°C for 24 hours and then transferred to liquid nitrogen tanks (-196°C) for long-term storage.
 - Tissue samples were snap-frozen in liquid nitrogen and later transferred to -80°C freezers.
- **Online database of clinical data and another database for tracking the location of each sample in freezers**

Special measures of ICCBB

- Collecting and storing a variety of biological samples from patients (including plasma, PBMC, serum, urine, and hair) and their parents (plasma and PBMC),
- Cooperation with inter-university centers outside of Tehran (Mashhad and Uremia)
- Using the vacume system (TissueSAFE® device) to preserve the tissue in a fresh way for the first time in Iran,
- launching an online database to recording medical data
- Finally setting up a bilingual website for announcing at the national and international levels





ic Congenital H
ders Research C
زی های فونی ماد



WBC (count) :

PMN :

MONO :

Blast :

Others :

RBC :

Pr :

Hct :

MCH :

PLT :

MPV :

LDH :

B-HCG :

HVA 24 hr urine :

L :

EOS :

HB :

Glu :

MCV :

MCHC :

RDW :



Ferritin :

Alpha-fetoprotein :

VMA 24 hr urine :

Fibrinogen :

☐ تجمع مایع در پرینگارد



Original article

The Iranian Childhood Cancer Biobank

Peyman Eshghi ¹, Nasrin Dehghan-Nayeri ^{1*}, Maryam Kazemi Aghdam ², Yalda Nilipour ², Mohsen Rouzrokh ³, Zahra Badii ⁴, Hamid Farhangi ⁴, Mehran Noroozi ⁵, Hasan Reza Mohammadi ⁶, Ehsan Moradi ⁶, Samin Alavi ¹, Leily Mohajerzadeh ³, Shahin Shamsian ¹, Ahmad Khaleghnejad Tabari ³, Javad Ghoroubi ³, Nader Momtazmanesh ¹, Mehdi Sarafi ³, Reza Shojaeian ⁷, Paria Dehghanian ⁸, Parastoo Molaei Tavana ⁹

¹Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Pediatric Pathology Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³Pediatric Surgery Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁴Department of Pediatric Hematology & Oncology, Dr. Sheikh Pediatric Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

⁵Department of Pediatrics, Urmia University of Medical Sciences, Urmia, Iran

⁶Department of Neurosurgery, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁷Department of Pediatric Surgery, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran

⁸Akbar Children's Hospital, Mashhad, Iran

⁹Department of Pediatrics, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Acknowledgements

We greatly appreciate the staff of the pathology, surgery, and oncology departments of : Mofid Children's Hospital in Tehran; Dr. Sheikh Hospital and Akbar Hospital in Mashhad; and Shahid Motahari Hospital in Urmia. Also, while honoring the memory of the late Dr. Kourosh Goudarzi-Pour who was one of the main collaborators of the project at the beginning, we would also like to acknowledge the contributions of Prof. Hasan Abolghasemi, Prof. Shahla Ansari, Prof. Mohammad-Ali Ehsani, Dr. Sasan Hejazi, Dr. Aziz Eghbali, Dr. Mohammad Kaji, Dr. Fatemeh Malek, Dr. Navid Zavar, Dr. Gholamreza Ebrahimi-Seraj, Dr. Maliheh Khodami, Dr. Ali Ghasemi, Dr. Farid Ghazizadeh.




Figure 2 The number and age-related percentages of collected samples

Totally, from January 2017 to July 2022 (three and a half years), 8,000 aliquoted samples from 720 patients and their parents have been processed and stored.




Figure 1. The number and percentage of collected samples

A first detected patients
B relapsed patients






Figure 3. Percentages of new case patients and relapsed patients

Table 1. The number and percentage of collected samples

<i>Diagnosis</i>	<i>Number of patients</i>	<i>Percentage of patients</i>
Leukemia	294	40.83%
ALL	262	36.39%
AML	28	3.89%
CML	3	0.42%
MPAL	1	0.14%
Solid tumors	284	39.44%
Neuroblastoma tumors	88	12.22%
Kidney tumors	77	10.69%
Germ cell tumors	30	4.17%
Liver tumors	23	3.19%
Lymphoma tumors	22	3.06%
Soft tissue tumors	22	3.06%
PNET	7	0.97%
Rare tumors	15	2.08%
CNS	112	15.56%
Glioma	51	7.08%
Ependymoma	17	2.36%
Medulloblastoma	14	1.94%
Craniopharyngioma	10	1.39%
ATRT	9	1.25%
Rare tumors	11	1.53%
Other	30	4.17%
Non-malignant tumors	30	4.17%




Plasma samples of Rhabdomyosarcoma (n=10)



شکل 31. تعداد نمونه های پلاسمای خون سیتراته و EDTA بیماران (و والدین) با تشخیص تومور رابدومیوسارکوما (ستون سبز رنگ تعداد الیکوت های موجود و ستون آبی رنگ تعداد بیماران را نشان می دهد)


PBMC samples of Rhabdomyosarcoma (n=10)



شکل 32. تعداد نمونه های PBMC خون سیتراته و EDTA بیماران (و والدین) با تشخیص تومور رابدومیوسارکوما (ستون سبز رنگ تعداد الیکوت های موجود و ستون آبی رنگ تعداد بیماران را نشان می دهد)

Disorders Research Center

مرکز تحقیقات بیماری های فوئی مادرزادی کودکان



Review

The dispersion of pediatric cancer biobanks in the Middle East: a global review of available resources

Peyman Eshghi¹, Nasrin Dehghan-Nayeri¹

¹Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Table 1. The dispersion of pediatric cancer biobanks in the Middle East.

Biobank name	Country	Establishment year	Stored samples
KHCC biobank	Jordan	2011	tissue, blood, and bone marrow, tumor tissue
CCHEBBR	Egypt	2014	blood derivatives, CSF, and malignant/normal tissue samples
ICCBB	Iran	2017	fresh tissue (malignant), plasma, peripheral blood mononuclear cells from blood and bone marrow, serum, urine, and hair
SPCB	Qatar	2021	blood, tissue, and fluid samples

